Smith & Nephew’s (SN) “Hold” Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reiterated their hold rating on shares of Smith & Nephew (LON:SN) in a research report report published on Thursday morning,Digital Look reports. Deutsche Bank Aktiengesellschaft currently has a GBX 1,400 target price on the stock.

Other analysts have also issued reports about the company. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,760 price objective on shares of Smith & Nephew in a report on Thursday, May 21st. Berenberg Bank reaffirmed a “hold” rating and set a GBX 13 target price on shares of Smith & Nephew in a research note on Friday, May 1st. Royal Bank Of Canada reiterated a “sector perform” rating and set a GBX 1,350 target price on shares of Smith & Nephew in a research report on Monday, June 29th. Shore Capital Group reissued a “buy” rating and issued a GBX 1,000 price target on shares of Smith & Nephew in a research note on Tuesday, July 21st. Finally, UBS Group reissued a “neutral” rating and issued a GBX 1,300 price target on shares of Smith & Nephew in a report on Tuesday, May 5th. Four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Smith & Nephew currently has a consensus rating of “Hold” and an average price target of GBX 1,340.11.

Smith & Nephew Stock Down 2.5%

Shares of Smith & Nephew stock opened at GBX 1,158.50 on Thursday. The stock has a market cap of £12.70 billion, a price-to-earnings ratio of 41.71, a PEG ratio of 0.46 and a beta of 0.68. The company has a current ratio of 2.57, a quick ratio of 0.84 and a debt-to-equity ratio of 62.90. The company has a fifty day simple moving average of GBX 1,134.48 and a 200-day simple moving average of GBX 1,195.89.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.